Vico Therapeutics is a company developing therapies for neurological conditions, including some of the SCAs. In April 2023, they announced that they have dosed the first patient in their Phase 1/2a clinical study evaluating VO659 for the treatment of SCA1, SCA3 and Huntington’s Disease (HD). This trial is designed to assess the safety and tolerability of different doses of VO659.
VO659 is a type of therapy called an antisense oligonucleotide (ASO). ASOs target the mutated gene, to prevent it from producing the protein which ultimately causes the condition. In this case, VO659 targets the genes that cause SCA1, SCA3 and HD.
This clinical trial is taking place in sites across Europe, and includes a UK site in London, at the London Ataxia Centre.
For more information read the full press release.
Click here to find out if you are eligible to take part in the trial.
